Perspective Therapeutics director Lori Woods acquires $49,999 in stock

In a recent transaction, Lori A. Woods, a director at Perspective Therapeutics, Inc. (NASDAQ:CATX), acquired 23,475 shares of the company’s common stock. The purchase comes as the stock trades near its 52-week low of $2.01, having declined over 83% in the past year. According to InvestingPro analysis, the company appears undervalued at its current market capitalization of $144.4 million. The shares were purchased at a price of $2.1299 each, amounting to a total transaction value of approximately $49,999. Following this acquisition, Woods holds 183,460 shares indirectly through the Woods Family Living Trust. Additionally, she maintains direct ownership of 4,807 shares. The transaction was executed on March 31, 2025, and was disclosed in a regulatory filing with the Securities and Exchange Commission. While the company holds more cash than debt on its balance sheet, InvestingPro subscribers can access 10+ additional key insights and a comprehensive Pro Research Report that provides deep-dive analysis of CATX’s financial health and growth prospects.

In other recent news, Perspective Therapeutics Inc has reported significant developments in its clinical trials and financial standing. The company disclosed its year-end results, highlighting a cash balance of $227 million, which is expected to sustain operations until late 2026. This financial stability supports ongoing research and development efforts, including the expansion of its VMT-α-NET trial to 30 patients, aimed at assessing the treatment’s safety and efficacy. Oppenheimer analysts maintained their Outperform rating with a $16 price target, citing the company’s robust cash position as a key factor.

Scotiabank (TSX:BNS) initiated coverage on Perspective Therapeutics with a Sector Outperform rating and a $15 price target, noting the company’s position as one of the few independent radiopharmaceutical entities. The bank expressed confidence in the potential of Perspective Therapeutics’ melanoma, FAP-alpha, and pre-targeting platform programs. Meanwhile, Lucid (NASDAQ:LCID) Capital Markets raised its price target to $20, maintaining a Buy rating after the company presented promising new data for its VMT-α-NET drug candidate at the ASCO GI 2025 conference. This data suggests the drug could be best-in-class, addressing previous concerns and boosting analyst confidence in its future performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.